http://www.advfn.com/nasdaq/rss.asp?symbol=AMLN Amylin Pharmaceuticals Company Newsfeed en Thu, 09 Aug 2012 08:24:09 EDT Thu, 09 Aug 2012 08:24:09 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53767981&headline=astrazeneca-bristol-myers-squibb-completes-purchase-of-amylin http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53767981&headline=astrazeneca-bristol-myers-squibb-completes-purchase-of-amylin <div class='newsbody'><p> LONDON--AstraZeneca PLC (AZN.LN) and Bristol-Myers Squibb said Thursday that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb Co (BMY), AstraZeneca has made an initial payment of 3.2 billion dollars to Amylin Pharmaceuticals... Thu, 09 Aug 2012 08:24:09 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53692554&headline=bristol-myers-executive-charged-with-insider-trading http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53692554&headline=bristol-myers-executive-charged-with-insider-trading <div class='newsbody'><p> Federal authorities arrested a Bristol-Myers Squibb Co. (BMY) executive Thursday on charges that he used inside information about the drug maker's acquisition targets to make more than $300,000 in illicit profits from stock-option trading. </p> <p> The U.S. Attorney's Office... Thu, 02 Aug 2012 12:30:06 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53692412&headline=u-s-charges-bristol-myers-executive-with-insider-trading http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53692412&headline=u-s-charges-bristol-myers-executive-with-insider-trading <div class='newsbody'><pre> By Peter Loftus </pre> <p> Federal authorities arrested a Bristol-Myers Squibb Co. (BMY) executive Thursday on charges that he used inside information about the drug maker's acquisition targets to make more than $300,000 in illicit profits from stock-option trading. </p> <p>... Thu, 02 Aug 2012 12:17:26 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53691281&headline=bristol-myers-pension-executive-robert-ramnarine-arrested-for http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53691281&headline=bristol-myers-pension-executive-robert-ramnarine-arrested-for <div class='newsbody'><p> Bristol-Myers Squibb Co. (BMY) executive Robert Ramnarine has been arrested by the Federal Bureau of Investigation and charged with insider trading, Bloomberg News reported Thursday. </p> <p> The FBI alleges that Ramnarine, executive director of pensions and savings, profited... Thu, 02 Aug 2012 11:07:11 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53607461&headline=evercore-2nd-quarter-profit-climbs-19-on-higher-investment-banking http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53607461&headline=evercore-2nd-quarter-profit-climbs-19-on-higher-investment-banking <div class='newsbody'><pre> By Brett Philbin </pre> <p> Boutique advisory firm Evercore Partners Inc. (EVR) posted a 19% rise in second-quarter earnings as the company benefited from a string of deal closings despite a tough market environment. </p> <p> Adjusted revenue in investment banking jumped 35... Thu, 26 Jul 2012 10:24:24 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53587756&headline=bristol-myers-profit-falls-28 http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53587756&headline=bristol-myers-profit-falls-28 <div class='newsbody'><p> Bristol-Myers Squibb Co.'s (BMY) second-quarter profit declined 28%, as sales were eroded by recent patent expirations for top-selling drugs including the anticlotting pill Plavix. </p> <p> The New York drug maker also lowered its forecast of full-year 2012 earnings. </p> <p>... Wed, 25 Jul 2012 08:20:16 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53587276&headline=bristol-myers-2nd-quarter-profit-falls-28-on-drug-patent-expirations http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=53587276&headline=bristol-myers-2nd-quarter-profit-falls-28-on-drug-patent-expirations <div class='newsbody'><pre> By Peter Loftus </pre> <p> Bristol-Myers Squibb Co.'s (BMY) second-quarter profit declined 28%, as sales were eroded by recent patent expirations for top-selling drugs including the anticlotting pill Plavix. </p> <p> The New York drug maker also lowered its forecast of full-year... Wed, 25 Jul 2012 08:00:01 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52967931&headline=bristol-sees-commercial-muscle-accelerating-sales-of-bydureon http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52967931&headline=bristol-sees-commercial-muscle-accelerating-sales-of-bydureon <div class='newsbody'><pre> By Peter Loftus </pre> <p> Bristol-Myers Squibb Co. (BMY) hopes its commercial muscle will help accelerate sales of new diabetes drug Bydureon, which Bristol stands to obtain with its proposed $5.3 billion purchase of Amylin Pharmaceuticals Inc. (AMLN). </p> <p> The initial... Mon, 02 Jul 2012 11:53:36 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52953021&headline=bristol-myers-to-buy-amylin-pharmaceuticals-for-5-3-billion http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52953021&headline=bristol-myers-to-buy-amylin-pharmaceuticals-for-5-3-billion <div class='newsbody'><p> Bristol-Myers Squibb Co. (BMY) will buy Amylin Pharmaceuticals (AMLN) for about $5.3 billion, or $31 a share, the companies announced Friday. The transaction was unanimously approved by both boards of directors, the companies said. Including a contractual payment obligation... Fri, 29 Jun 2012 23:36:26 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52717102&headline=novo-nordisks-victoza-more-efficient-than-peers-in-new-study http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52717102&headline=novo-nordisks-victoza-more-efficient-than-peers-in-new-study <div class='newsbody'><p> COPENHAGEN--The world's largest insulin maker Novo Nordisk A/S (NOVO-B.KO) said late Sunday fresh study results show that its diabetes 2-treating drug Victoza more efficiently lowers blood sugar levels and helps patients lose weight than key competitors' drugs. </p> <p> According... Sun, 10 Jun 2012 20:35:15 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52713681&headline=sanofis-lantus-cuts-blood-sugar-more-than-mercks-januvia-in http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52713681&headline=sanofis-lantus-cuts-blood-sugar-more-than-mercks-januvia-in <div class='newsbody'><p> --Sanofi says data strengthen efficacy profile of Lantus in early treatment </p> <p> --Lantus, however, is tied to more low-blood-sugar episodes than Januvia </p> <p> --Amylin's Byetta is superior to older diabetes drug in separate study </p> <pre> By Peter Loftus </pre> <p>... Sat, 09 Jun 2012 08:30:11 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52661183&headline=amylin-is-said-to-draw-first-round-bids-of-up-to-29-share-bloomberg http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52661183&headline=amylin-is-said-to-draw-first-round-bids-of-up-to-29-share-bloomberg <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Diabetes drug maker Amylin Pharmaceuticals Inc. (AMLN) drew four first-round bids valuing the company at $25 to $29 a share, with Pfizer Inc. (PFE) dropping out of the process, Bloomberg News reported Monday on its website, citing people with knowledge... Tue, 05 Jun 2012 09:10:47 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52150661&headline=icahn-suit-against-amylin-dropped-after-talks-with-ceo http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52150661&headline=icahn-suit-against-amylin-dropped-after-talks-with-ceo <div class='newsbody'><pre> DOW JONES NEWSWIRES </pre> <p> Activist Investor Carl Icahn said he has dropped a lawsuit against Amylin Pharmaceuticals Inc. (AMLN) that sought to extend the drug maker's board-nomination deadline after discussions with the company's chief executive, Daniel Bradbury. </p> <p>... Wed, 25 Apr 2012 14:53:05 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52074199&headline=fda-is-asked-to-remove-novo-nordisk-diabetes-drug-from-market http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=52074199&headline=fda-is-asked-to-remove-novo-nordisk-diabetes-drug-from-market <div class='newsbody'><pre> By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES </pre> <p> WASHINGTON -(Dow Jones)- A consumer advocacy group is asking the U.S. Food and Drug Administration to remove Novo Nordisk's (NVO, NOVO-B.KO) diabetes drug Victoza from the market because of safety concerns. </p> <p>... Thu, 19 Apr 2012 13:53:31 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=51938484&headline=icahn-files-lawsuit-against-amylin-to-force-nomination-extension http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=51938484&headline=icahn-files-lawsuit-against-amylin-to-force-nomination-extension <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Carl Icahn ratcheted up the pressure on Amylin Pharmaceuticals Inc. (AMLN) by filing a lawsuit against the drug maker in an effort to extend its board-nomination deadline as the activist investor continues to push for a sale of the company. </p> <p>... Mon, 09 Apr 2012 13:08:09 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=51803023&headline=amylin-has-rejected-3-5-billion-buyout-bid-by-bristol-myers http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=51803023&headline=amylin-has-rejected-3-5-billion-buyout-bid-by-bristol-myers <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Amylin Pharmaceuticals Inc. (AMLN) has rejected an unsolicited $3.5 billion offer from Bristol-Myers Squibb Co. (BMY), made earlier this year, Bloomberg News reported Wednesday, citing two people with knowledge of the matter. </p> <p> Bristol-Myers... Wed, 28 Mar 2012 10:08:30 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=51748537&headline=amylin-eu-approves-diabetes-treatment-byetta-with-basal-insulin http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=51748537&headline=amylin-eu-approves-diabetes-treatment-byetta-with-basal-insulin <div class='newsbody'><p> DOW JONES NEWSWIRES </p> <p> Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly &amp; Co. (LLY) said the European Commission approved its type 2 diabetes treatment Byetta as an add-on therapy to basal insulin. </p> <p> The drug makers said Byetta with titrated basal insulin improves... Fri, 23 Mar 2012 09:08:11 EDT http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=50957583&headline=us-stocks-edge-lower-as-europes-debt-flashpoints-weigh http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=50957583&headline=us-stocks-edge-lower-as-europes-debt-flashpoints-weigh <div class='newsbody'><p> --U.S. stocks end lower, but recover to finish nearly flat </p> <p> --Greece's debt talks at standoff; Portugal borrowing costs rise to euro-era highs </p> <p> --Financial stocks tumble on Goldman Sachs bank downgrades; BofA weighs on Dow </p> <p> --Data show incomes picked... Mon, 30 Jan 2012 17:42:15 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=50946166&headline=us-stock-futures-lower-on-renewed-worries-over-greece http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=50946166&headline=us-stock-futures-lower-on-renewed-worries-over-greece <div class='newsbody'><p> By Barbara Kollmeyer </p> <p> U.S. stock index futures fell on Monday, tracking losses in Asia and Europe, as investors eyed a European Union summit amid fresh worries over Greece's ability to sort out its financial difficulties. </p> <p> Futures for the Dow Jones Industrial... Mon, 30 Jan 2012 08:02:33 EST http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=50931124&headline=fda-approves-amylins-bydureon-diabetes-drug-after-delays http://www.advfn.com/nasdaq/StockNews.asp?stocknews=AMLN&article=50931124&headline=fda-approves-amylins-bydureon-diabetes-drug-after-delays <div class='newsbody'><pre> By Peter Loftus Of DOW JONES NEWSWIRES </pre> <p> The U.S. Food and Drug Administration approved Amylin Pharmaceuticals Inc.'s (AMLN) diabetes drug Bydureon following a prolonged regulatory process in which the agency required extra testing to alleviate safety concerns. </p> <p>... Fri, 27 Jan 2012 16:12:26 EST